A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin (CLEE011 XUS02T)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Ribociclib (Primary)
- Indications Gastrointestinal cancer
- Focus Therapeutic Use
- 20 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.
- 19 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2015 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.